^
    over3years
    CAN017, a novel anti-HER3 antibody, exerted great potency in mouse avatars of esophageal squamous cell carcinoma with NRG1 as a biomarker. (PubMed, Am J Cancer Res)
    These results were also validated in PDX models of cohort 2 indicated as the powerful anti-tumor activity of CAN017 in PDX models with NRG1 high expression. In our study, HER3-targeting therapy was first demonstrated to have potency in inhibiting ESCC tumor growth, and NRG1 served as a predictive biomarker to screen patients in future clinical trials.
    Preclinical • Journal
    |
    NRG1 (Neuregulin 1)
    |
    ERBB3 expression
    |
    AV-203